Clinical trial · Interventional
Role of Preoperative Tapentadol in Reduction of Perioperative Analgesic Requirement After Breast Conservative Surgery in Cancer Patients.
NCT07320781CI-TRIAL-00100397completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study evaluated the preemptive analgesic efficacy of Tapentadol in reducing peri operative analgesic requirements among patients undergoing breast cancer surgery.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Placebo | Other | — | UNRESOLVED |
| Tapentadol | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Tapentadol
- description
- Control drug (Tapentadol )
- interventionNames
- Drug: Tapentadol
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- description
- Placebo sodium bicarbonate/ peppermint oil tablet
- interventionNames
- Other: Placebo
Primary outcomes (1)
- measure
- Intraoperative and postoperative morphine consumption
- timeFrame
- During the course of surgery and up to 4 hours surgery
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: 1. 18-60 years 2. ASA 1,2,3 3. Patients scheduled for breast conservation surgery - Exclusion Criteria: 1. Patient refusal 2. CKD greater than 3 3. BMI greater than 35 4. Known drug allergy -
References
Publications (0)
Data not yet available
No reference posted for this study.